‘One size does not fit all’: Cirrhosis care access, mortality vary widely worldwide
LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver…
LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver…
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.